TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00733083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,1 mg/kg of oxycodone
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 0,1 mg/kg
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0,5 mg/kg
Description: solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: solution for injection one injection in the beginning of anesthesia
Study: NCT01047332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partially Covered Wallstent
Description: Partially covered wallstent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Wallstent
Description: Uncovered wallstent
Study: NCT02991716

Intervention type: OTHER
Intervention: recorded patients
Description: No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
Study: NCT01381991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-scan
Description: For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
Study: NCT04288336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Diary
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventative Dietary Intervention
Description: Follow intermittent fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02971540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
Study: NCT02295852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LOW-SODIUM LOW LIPID CALCIUM RICH DIET
Description: 1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LOW-SODIUM LOW LIPID DIET
Description: 2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
Study: NCT03787238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation
Description: non-invasive vagus nerve stimulation using the gammaCore Sapphire device
Study: NCT02971540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
Study: NCT00842998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab or Lapatinib
Description: Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab or Lapatinib
Description: Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
Study: NCT02879994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01029171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based balance and strength retraining exercise program.
Description: A 12-month home-based balance and strength restraining program delivered by a physical therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control; usual care
Description: Usual care as prescribed by geriatrician.
Study: NCT02753387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9 %
Description: 4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
Study: NCT02519634

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super-Mini Percutaneous Nephrolithotomy
Description: Patients undergo Super-Mini Percutaneous Nephrolithotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retrograde Intrarenal Surgery
Description: Patients undergo Retrograde Intrarenal Surgery
Study: NCT01255410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^5 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Single dose of placebo vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Single dose of placebo vaccine delivered intranasally

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Single dose of placebo vaccine delivered intranasally
Study: NCT00945204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate care clinics (ICCs)
Description: The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
Study: NCT02760472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinoleic
Description: Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
Study: NCT03987659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation protocols that promote release of dECMs
Description: Irrigation protocols that promote release of dECMs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Irrigation protocols
Description: Conventional Irrigation protocols
Study: NCT03749148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: anti-IL4-Receptor alpha

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04210804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)
Description: 200mls Smoothie

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)
Description: 200mls Smoothie
Study: NCT00560586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1 puff each nostril (32 micrograms) at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 puff each nostril at bedtime
Study: NCT04163835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1/2 Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twice Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g.
Study: NCT03293472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle
Study: NCT03472976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous Cream B.P.
Description: Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Description: Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Description: Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
Study: NCT03334799

Intervention type: DEVICE
Group type: OTHER
Intervention: sacroiliac belt
Description: standing and walking with the belt on and with the belt off
Study: NCT01701271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair loss prevention lotion
Description: For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
Study: NCT02744027

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)
Description: Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.

Intervention type: OTHER
Group type: OTHER
Intervention: Heavy Weighted T2 Imaging (T2W)
Description: Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Lymph Node Access
Description: The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite.
Study: NCT01361269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin and clindamycin
Description: The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
Study: NCT01890213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Study: NCT00561470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Description: The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Description: The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Study: NCT04533191

Intervention type: PROCEDURE
Intervention: LAL IOL lens
Description: Standard of care Cataract surgery with IOL placement
Study: NCT02987569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mConnect plus mobile connections to multidisciplinary professionals & peers
Description: mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPad use plus one mobile connections to multidisciplinary professionals & peers
Description: iPad with a data plan and one professionally moderated iPad visual meeting with peers.